Literature DB >> 30483748

HOXA5 inhibits the proliferation and induces the apoptosis of cervical cancer cells via regulation of protein kinase B and p27.

Zefei Wang1, Chunzhi Yu2, Hong Wang3.   

Abstract

Homeobox A5 (HOXA5) is a member of the homeobox gene (HOX) family, which plays an important role in the development of various malignant tumors. Here, we speculated that HOXA5 has an effect on cervical cancer development. In our study, we aimed to explore the role and molecular mechanism of HOXA5 in regards to the cell proliferation and apoptosis in cervical cancer. We found that expression levels of HOXA5 measured by RT‑qPCR and western blot assays in cervical cancer cell lines and tissues were both significantly downregulated. We performed a gain‑of‑function experiment by the transfection with pcDNA.3.1‑HOXA5 in ME‑180 and HT‑3 cells to overexpress HOXA5, and the caspase‑3 activity measured by caspase‑3 activity assay kit and cell apoptosis detected by flow cytometry were obviously promoted. Meanwhile, cell proliferation tested by BrdU assay, invasion determined by Transwell and cell viability tested by MTT were inhibited. Moreover, protein kinase B (AKT) was activated by incubation with SC79 (AKT activator; 1 µg/ml) after HOXA5 overexpression, and reversed the effect of HOXA5 overexpression on p27 expression. Additionally, significant elevation of AKT activation measured by western blot analysis abrogated the effect of HOXA5 on caspase‑3 activity, cell apoptosis, proliferation, invasion and cell viability. Taken together, this study revealed that HOXA5 inhibits cervical cancer progression by regulating AKT/p27, proposing the potential role of HOXA5 in the prevention and treatment of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30483748     DOI: 10.3892/or.2018.6874

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Mice lacking uterine enhancer of zeste homolog 2 have transcriptomic changes associated with uterine epithelial proliferation.

Authors:  Ana M Mesa; Jiude Mao; Manjunatha K Nanjappa; Theresa I Medrano; Sergei Tevosian; Fahong Yu; Jessica Kinkade; Zhen Lyu; Yang Liu; Trupti Joshi; Duolin Wang; Cheryl S Rosenfeld; Paul S Cooke
Journal:  Physiol Genomics       Date:  2019-12-16       Impact factor: 3.107

2.  HOXA5 inhibits the proliferation and neoplasia of cervical cancer cells via downregulating the activity of the Wnt/β-catenin pathway and transactivating TP53.

Authors:  Hong-Mei Ma; Nan Cui; Peng-Sheng Zheng
Journal:  Cell Death Dis       Date:  2020-06-04       Impact factor: 8.469

3.  HOXA5 Expression Is Elevated in Breast Cancer and Is Transcriptionally Regulated by Estradiol.

Authors:  Imran Hussain; Paromita Deb; Avisankar Chini; Monira Obaid; Arunoday Bhan; Khairul I Ansari; Bibhu P Mishra; Samara A Bobzean; S M Nashir Udden; Prasanna G Alluri; Hriday K Das; Robert Matthew Brothers; Linda I Perrotti; Subhrangsu S Mandal
Journal:  Front Genet       Date:  2020-12-15       Impact factor: 4.599

4.  The Roles of the Histone Protein Modifier EZH2 in the Uterus and Placenta.

Authors:  Ana M Mesa; Cheryl S Rosenfeld; Geetu Tuteja; Theresa I Medrano; Paul S Cooke
Journal:  Epigenomes       Date:  2020-09-02

Review 5.  Molecular implications of HOX genes targeting multiple signaling pathways in cancer.

Authors:  U Sangeetha Shenoy; Divya Adiga; Shama Prasada Kabekkodu; Keith D Hunter; Raghu Radhakrishnan
Journal:  Cell Biol Toxicol       Date:  2021-10-06       Impact factor: 6.691

6.  Hoxa5 Inhibits the Proliferation and Induces Adipogenic Differentiation of Subcutaneous Preadipocytes in Goats.

Authors:  Dingshuang Chen; Yaqiu Lin; Nan Zhao; Yong Wang; Yanyan Li
Journal:  Animals (Basel)       Date:  2022-07-21       Impact factor: 3.231

7.  HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer.

Authors:  Clara Yuri Kim; Yu Cheon Kim; Ji Hoon Oh; Myoung Hee Kim
Journal:  J Cancer       Date:  2021-06-01       Impact factor: 4.207

8.  Assessment of Expression of Homeobox A5 in Endometrial Cancer on the mRNA and Protein Level.

Authors:  Konrad Dziobek; Marcin Oplawski; Nikola Zmarzły; Beniamin O Gabarek; Robert Kiełbasiński; Kamil Kiełbasiński; Przemysław Kieszkowski; Karol Talkowski; Dariusz Boroń
Journal:  Curr Pharm Biotechnol       Date:  2020       Impact factor: 2.837

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.